Zum Inhalt

HealthOSArzneimittel

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-26 · 1181 Präparate · 62955 Quellenpassagen · 167 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (1)

Wechselwirkungen · Kaletra

Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 19–20

HOS-108904 · Präparat HOS-093083

19 Rifampicin Lopinavir: Co-administration of Kaletra with Large decreases in lopinavir rifampicin is not recommended as concentrations may be observed the decrease in lopinavir due to CYP3A induction by concentrations may in turn rifampicin. significantly decrease the lopinavir therapeutic effect. A dose adjustment of Kaletra 400 mg/400 mg (i.e. Kaletra 400/100 mg + ritonavir 300 mg) twice daily has allowed compensating for the CYP 3A4 inducer effect of rifampicin. However, such a dose adjustment might be associated with ALT/AST elevations and with increase in gastrointestinal disorders. Therefore, this co-administration should be avoided unless judged strictly necessary. If this co-administration is judged unavoidable, increased dose of Kaletra at 400 mg/400 mg twice daily may be administered with rifampicin under close safety and therapeutic drug monitoring. The Kaletra dose should be titrated upward only after rifampicin has been initiated (see section 4.4). Antipsychotics Lurasidone Due to CYP3A inhibition by The concomitant administration lopinavir/ritonavir, with lurasidone is contraindicated concentrations of lurasidone are (see section 4.3). expected to increase. Pimozide Due to CYP3A inhibition by Concomitant administration of lopinavir/ritonavir, Kaletra and pimozide is concentrations of pimozide are contraindicated as it may increase expected to increase. the risk of serious haematologic abnormalities or other serious adverse effects from this agent (see section 4.3) Quetiapine Due to CYP3A inhibition by Concomitant administration of lopinavir/ritonavir, Kaletra and quetiapine is concentrations of quetiapine are contraindicated as it may increase expected to increase. quetiapine-related toxicity.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) pimozide (HOS-085600) lurasidone (HOS-086148)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 0cd97f605d9ff9f95bd037eca67e54d94e990128412fa438a0aa4c28977553c1 · Zeichen 38367–41870 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.